Personalized vaccine for lymphoma patients extends disease-free survival by nearly 2 years
The personalized vaccine is effective in preventing recurrence among certain follicular lymphoma patients with a specific protein on their tumor cells. The vaccine improves disease-free survival by nearly two years compared to placebo treatments.